Close

Analyst Ratings for Conatus Pharmaceuticals (CNAT) [Neutrals]

All Latest Ratings for CNAT

CNAT Rating Summary

  |   Expand Research on CNAT
Overall Rating: NEUTRAL   Rating Trend: =   Avg. $ Target: N/A
Rating Score: 4.3 / 10   Percentile Rank: 36%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
3/26/2019 Roth/MKM Yasmeen Rahimi Downgrade Neutral
(Buy)		 1.70
(N/A)		 1.28
(0.56)		 -56.25% Details
3/22/2019 H.C. Wainwright Ed Arce Downgrade Neutral
(Buy)		 1.50
(8.00)		 2.88
(0.56)		 -80.56% Details